McAdam LLC Sells 377 Shares of Agilent Technologies, Inc. (NYSE:A)

McAdam LLC lessened its position in Agilent Technologies, Inc. (NYSE:A) by 13.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,450 shares of the medical research company’s stock after selling 377 shares during the period. McAdam LLC’s holdings in Agilent Technologies were worth $341,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. DAVENPORT & Co LLC acquired a new stake in shares of Agilent Technologies during the third quarter worth about $307,000. Valeo Financial Advisors LLC bought a new position in Agilent Technologies in the third quarter valued at approximately $213,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Agilent Technologies by 2.0% in the third quarter. Harbor Capital Advisors Inc. now owns 6,231 shares of the medical research company’s stock valued at $697,000 after buying an additional 123 shares during the period. Commonwealth Equity Services LLC boosted its holdings in shares of Agilent Technologies by 0.9% in the third quarter. Commonwealth Equity Services LLC now owns 33,586 shares of the medical research company’s stock valued at $3,756,000 after buying an additional 313 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Agilent Technologies by 11.8% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 80,522 shares of the medical research company’s stock worth $9,004,000 after acquiring an additional 8,500 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently commented on A shares. Barclays boosted their price objective on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research report on Wednesday, April 10th. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and upped their price objective for the stock from $145.00 to $163.00 in a research report on Friday, April 5th. Citigroup lifted their target price on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Oppenheimer upped their price target on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Finally, Evercore ISI lifted their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Stock Up 1.3 %

Shares of A stock opened at $139.59 on Tuesday. Agilent Technologies, Inc. has a 52-week low of $96.80 and a 52-week high of $151.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.04 and a current ratio of 2.68. The stock has a market cap of $40.91 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 4.17 and a beta of 1.11. The firm’s 50-day moving average is $141.69 and its 200-day moving average is $131.02.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The business’s revenue was down 5.5% on a year-over-year basis. During the same period last year, the firm posted $1.37 earnings per share. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were given a $0.236 dividend. This represents a $0.94 annualized dividend and a dividend yield of 0.68%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s payout ratio is presently 22.38%.

Insider Activity

In other news, CEO Michael R. Mcmullen sold 52,297 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $150.00, for a total value of $7,844,550.00. Following the transaction, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at approximately $38,086,350. The disclosure for this sale can be found here. Insiders have sold 61,610 shares of company stock valued at $9,220,333 over the last ninety days.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.